RGD Reference Report - The impact of smoking on clinical features of Behcet's disease patients with glutathione S-transferase polymorphisms. - Rat Genome Database

RGD Reference Report - The impact of smoking on clinical features of Behcet's disease patients with glutathione S-transferase polymorphisms. - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

General

The impact of smoking on clinical features of Behcet's disease patients with glutathione S-transferase polymorphisms.
Authors:	Ozer, HT Gunesacar, R Dinkci, S Ozbalkan, Z Yildiz, F Erken, E
Citation:	Ozer HT, etal., Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S14-7. Epub 2012 Oct 8.
RGD ID:	7794848
Pubmed:	PMID:22766250 (View Abstract at PubMed)
OBJECTIVES: Various cancer studies have suggested that polymorphism of GSTM1 may influence the ability to detoxify chemicals in cigarette smoke. In the present study the effect of smoking on clinical features of Behcet's disease were investigated in patients having GST-M1 and/or -T1 null polymorphisms. METHODS: Ninety-seven patients meeting International Study Group Criteria for Behcet's disease (63 male, 34 female) and 172 healthy controls (94 male, 78 female) were included into the study. GST-M1 and -T1 polymorphisms were investigated using polymerase chain reaction-restriction fragment length polymorphism technique. RESULTS: Frequency of GSTM1- and/or GSTT1-null polymorphisms were comparable between the Behcet and the control groups. Smoking patients with GSTM1 null-polymorphism have decreased risk of developing papulopustuler lesions (OR=0.227 [0.063-0.818], chi2=5.463, p=0.019). Non-smoking patients with GSTM1 null-polymorphism has increased risk for having chronic arthritis (OR=5.988 [0.845-43.478]) but smoking patients with GSTM1 null-polymorphism have decreased risk (OR=0.741 [0.593-0.926]). GSTT1 null-polymorphism is associated with the presence of venous insufficiency (chi2=6.273, p=0.012, OR=2.740 [1.224-6.135]); smoking further increases the risk (chi2=7.840, OR=3.333 [1.412-7.874], p=0.005). GSTM1 null-polymorphism seemed to effect development of large vessel vasculitis (OR=1.158 [0.981-1.367], chi2=4.760, p=0.029). Male smoker Behcet patients even have more risk (OR=1.250 [0.971-1.610]). CONCLUSIONS: Several manifestations of Behcet's disease may be influenced by smoking, and this effect can be augmented in patients carrying GST gene polymorphism, which code enzymes crucial for the detoxification of chemicals.

Only show annotations with direct experimental evidence (0 objects hidden)

Object Symbol	Species	Term	Qualifier	Evidence	With	Notes	Source	Original Reference(s)
GSTM1	Human	erythema nodosum	susceptibility	IAGP		associated with Behcet Syndrome and DNA:deletion:: (human)	RGD
Gstm1	Rat	erythema nodosum	susceptibility	ISO	GSTM1 (Homo sapiens)	associated with Behcet Syndrome and DNA:deletion:: (human)	RGD
Gstm1	Mouse	erythema nodosum	susceptibility	ISO	GSTM1 (Homo sapiens)	associated with Behcet Syndrome and DNA:deletion:: (human)	RGD
GSTT1	Human	venous insufficiency	susceptibility	IAGP		associated with Behcet Syndrome and DNA:deletion:cds (human)	RGD
Gstt1	Rat	venous insufficiency	susceptibility	ISO	GSTT1 (Homo sapiens)	associated with Behcet Syndrome and DNA:deletion:cds (human)	RGD
Gstt1	Mouse	venous insufficiency	susceptibility	ISO	GSTT1 (Homo sapiens)	associated with Behcet Syndrome and DNA:deletion:cds (human)	RGD

Genes (Rattus norvegicus)


Gstm1 (glutathione S-transferase mu 1)	Gstt1 (glutathione S-transferase theta 1)

Genes (Mus musculus)


Gstm1 (glutathione S-transferase, mu 1)	Gstt1 (glutathione S-transferase, theta 1)

Genes (Homo sapiens)


GSTM1 (glutathione S-transferase mu 1)	GSTT1 (glutathione S-transferase theta 1)